Polyrizon (PLRZ) shares fell in their Nasdaq trading debut on Tuesday after the development-stage biotech company priced its $4.2 million initial public offering.
The stock was down about 66% in recent trading after opening at $1.64.
Polyrizon priced its IPO of 958,903 units at a combined price of $4.38 per unit, with each unit each consisting of one share and three warrants to buy one share per warrant, with an initial exercise price of $4.38 per share.
Aegis Capital has a 45-day option to acquire up to 143,835 additional units. The offering is expected to close Wednesday.
Price: 1.47, Change: -2.91, Percent Change: -66.44
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.